Maarten van der Doelen

Chapter 4

Reference Opioid use 9.00 (1.66-48.70)* 3.86 (0.94-15.76) 0.10 (0.01-0.80)* 3.21 (0.75-13.74) 0.74 (0.14-3.98) Hemoglobin 1.34 (0.50-3.55) 1.22 (0.48-3.05) 2.29 (1.14-4.62)* 1.90 (0.68-5.29) 0.91 (0.36-2.31) Partnership 0.66 (0.07-6.00) NE - 0.91 (0.25-3.36) 1.75 (0.30-10.27) NE - 1.00 (0.92-1.09) 1.04 (0.96-1.13) 0.99 (0.94-1.05) 1.01 (0.93-1.10) 1.04 (0.96-1.14)

Fluctuating (N=9)

Class 6

OR (95% CI)

Alkaline phosphatase (log) 0.51 (0.04-7.54) 0.15 (0.01-2.83) 0.12 (0.02-0.90)* 3.72 (0.41-34.12) 0.12 (0.01-2.79) Prostate-specific antigen (log) 0.90 (0.34-2.42) 0.55 (0.22-1.35) 1.29 (0.62-2.30) 3.05 (0.98-9.53) 1.11 (0.41-3.04) Number of prior therapies 1.03 (0.51-2.08) 1.17 (0.60-2.26) 1.27 (0.80-2.00) 2.17 (1.12-4.22)* 0.92 (0.44-1.89) ECOG performance status

ECOG 1 2.89 (0.48-17.49) 10.11 (1.14-89.43)* 0.90 (0.34-2.44) 7.22 (0.78-67.14) 1.93 (0.38-9.67) ECOG 2-3 6.50 (0.88-47.90) 8.67 (0.67-112.04) 0.27 (0.03-2.46) 13.00 (1.14-147.82)* 1.93 (0.38-9.67) CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NE, not evaluable due to low number of patients in class; OR, odds ratio. * P value <0.05

Improved (N=8)

Class 5

OR (95% CI)

Stable high (N=27)

Class 4

OR (95% CI)

(N=10)

Class 3

OR (95% CI)

Stable intermediate

Stable low (N=9)

Class 2

OR (95% CI)

Deteriorated (N=50)

Class 1

Table 3. Outcomes of trajectory analyses showing factors associated with class membership of health-related quality of life trajectories during radium-223 therapy. Age

100